4858美高梅 1


​The pharma business

A better pill from China


Chinese pharma firms are starting to develop new drugs for the global


  1. WALK into the Shanghai laboratories of Chi-Med, a biotech firm, and
    you encounter the sort of shiny, cutting-edge facilities common
    in any major pharma company in America, Europe or Japan.
    Chi-Med(和黄药业)has just had positive results in a late-stage
    trial of its drug for colorectal cancer, which is called
    Fruquintinib. If the drug is approved both in China and in Western
    markets it could be the very first prescription drug to be designed
    and developed entirely in China that will be on a path to global

  2. Given China’s ageing population, higher incomes and rising demand
    for health care it is clear why innovation in drugs is a priority
    for the country. Its national market for drugs has grown rapidly in
    recent years to become the world’s second-largest. It could grow
    from $108bn in 2015 to around 167bn dollars by 2020, according to an
    estimate from America’s Department of Commerce. By comparison,
    America spends about $400bn a year on drugs.
    2)鉴于中华夏族民共和国的老龄化人口、更高个人收入和不断提升的医疗保健须求,为什么在药物方面包车型地铁翻新成为那些国家的当务之急就清楚了。近日,中国药物的境内市镇火速增强,已经成为世界第2大药品市集。据United States际商业信用贷款银行务部审时度势,它能够从二〇一五年的1080亿美金升高到二零二零年的约1670亿日元。相比之下,United States在药物上一年消费了约五千亿澳元。

  3. Chinese firms mainly sell cheap,** generic medicines** that earn
    only razor-thin margins. The pharma industry is extremely
    fragmented, with thousands of tiny manufacturers and distributors.
    That helps explain the limited amount of finance that is available
    for investment in new medicines. Most Chinese pharma firms devote
    less than 5% of sales to R&D, according to a report last year from
    the World Health Organisation (big global drug firms typically spend
    14%-18% of sales on R&D). And the bulk of that spending goes to
    research into generics.


  1. But things are changing quickly. The government is encouraging the
    industry to consolidate, chiefly by raising standards for the
    quality of new medicines. It is also improving the country’s
    regulatory infrastructure, which should make it more efficient, and
    faster, to develop drugs. The value of deals in the health-care
    sector has been increasing as a result. ChinaBio, a research firm,
    reckons that over $40bn of foreign and local money went into the
    life sciences in China in 2016. In the same year just three Chinese
    biotech firms—CStone, Innovent and Ascletis—together raised more
    than $500m of financing.
    4)但整套正在火速改变。政坛在鼓励制药企合并,首要透过提升新技术药质量量标准的方法。它也在校订国家的禁锢基础设备,那应该使它更便捷、更便捷地开发药物。由此,医疗保健行业的贸易价值不断扩张。一家United States讨论公司ChinaBio测度,二零一四年超过400亿法郎的举世资金进入中华的生命科学(产业)。在一如既往年,仅三家中中原人民共和国生物科学和技术公司——香江基石家庄药业业、德雷斯顿信达生物以及马斯喀特歌礼生物科学和技术有限公司——就一块儿筹集了超越5亿欧元融通资金。

  2. Another boost is the arrival of talent from abroad, whether
    Chinese-born executives returning with a Western education or
    Westerners with experience of multinational pharmaceutical firms.
    Christian Hogg, the boss of Chi-Med—which was founded in 2000, has
    eight drugs in clinical development and listed on the NASDAQ stock
    exchange in 2016—used to work at Procter & Gamble, a global
    consumer-goods firm. Samantha Du, the firm’s very first scientific
    officer, was formerly an executive at Pfizer, an American pharma
    giant. Now known as the godmother of Chinese biopharma, she used to
    manage health-care investments for Sequoia Capital, a Silicon Valley
    venture-capital firm. In 2013 she helped found Zai Lab, which
    licenses late-stage drugs from Western pharma companies to
    develop and sell in China. Zai Lab also aims to develop innovative
    medicines in immuno-oncology.
    5)另3个推动要素是异域人才的来到,无论是接受西方教育又回国的华夏管理职员,依旧有跨国制药公司经历的天堂职员。贺隽是树立于两千年的和黄药业的业主,该铺面全部医疗开发的多种药品,并于二零一五年在纳斯达克股交所上市。他曾在天下消费品集团宝洁公司办事。该公司的第②个人专业出身的老董杜莹曾是United States制药业巨头辉瑞制药企业的执行官。以后他被叫作中中原人民共和国生物制药的教母,她曾为一家硅谷危机投资企业——红杉资本管理医疗保健投资。二〇一二年他推推搡搡创制(总部位于法国巴黎的生物科技(science and technology)公司)再鼎医药,该公司从西方制药公司取得最后药物许可证以在中原研究开发并销售。再鼎医药还致力于开发免疫肿瘤学下边包车型客车更新药物。

  3. Another firm attracting attention is BeiGene, an oncology firm based
    in Beijing, which has four clinical-stage drug candidates and which
    raised $158m in an IPO last year. Chi-Med’s Fruquintinib may even be
    beaten in the race to approval in America and Japan by a cancer drug
    called Epidaza from Chipscreen Biosciences of Shenzhen. China
    approved it in 2015.

  4. It is too early to say whether these innovative firms will remain
    rarities. Only a few large ones have emerged, since the industry
    is resisting consolidation. But the size of the local market will
    itself help the industry grow. And developing a drug in China is far
    cheaper than it is in America or Europe. Given the outrage at the
    high cost of drugs in America, in particular, there is every
    for Chinese firms to develop medicines for the global

一 、鉴于中国的老龄化人口、更高个人收入和不止升起的通常护理须求,为啥在药物方面包车型大巴换代成为那么些国家的当务之急就清楚了。

贰 、另贰个促进因素是外国人才的到来,无论是接受西方教育又回国的中华管理职员,依然有跨国制药集团经历的极乐世界人员。

叁 、尤其是,鉴于美利坚合众国药品价格昂贵引起愤怒,中华夏族民共和跨国集团业为海内外国商人场开发药品的动机十足